{"id":"moxifloxacin-ophthalmic-solution-0-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival erythema"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Taste perversion"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:11:53.747405","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual mechanism allows it to be effective against a wide range of ocular pathogens. When applied topically as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:00.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial keratitis"},{"name":"Bacterial corneal ulcer"},{"name":"Prophylaxis of bacterial infection following ocular surgery"}]},"_fixedFields":["pubmed(28)"],"trialDetails":[{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT05110001","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-08-03","conditions":"Acanthamoeba Keratitis, Fungal Keratitis","enrollment":330},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06363292","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2024-01-30","conditions":"Ophthalmological Agent Toxicity, Bacterial Conjunctivitis","enrollment":37},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT06163105","phase":"NA","title":"The Effect of Gland Expression on the Regeneration of Meibomian Gland","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-10-03","conditions":"Meibomian Gland Dysfunction","enrollment":64},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT05413980","phase":"","title":"Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-27","conditions":"Post Operative Endophthalmitis","enrollment":102},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05255107","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":468},{"nctId":"NCT05428683","phase":"NA","title":"Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery","status":"COMPLETED","sponsor":"Emad Abdel Aal Saliem","startDate":"2020-12-03","conditions":"Pharmacological Action","enrollment":84},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT05162625","phase":"PHASE2","title":"Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2021-12-10","conditions":"Endophthalmitis, Open Globe Injury, Moxifloxacin","enrollment":100},{"nctId":"NCT05079854","phase":"PHASE4","title":"Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2021-10-01","conditions":"Endophthalmitis, Trauma, Corneal","enrollment":100},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT04212429","phase":"PHASE1, PHASE2","title":"The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis Postoperative","enrollment":128},{"nctId":"NCT04214821","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis","enrollment":128},{"nctId":"NCT04403334","phase":"PHASE4","title":"Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin","status":"COMPLETED","sponsor":"Peregrine Eye and Laser Institute","startDate":"2018-01-02","conditions":"Cataract Senile, Endophthalmitis, Antibiotic Side Effect","enrollment":114},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":"Bacterial Conjunctivitis","enrollment":150},{"nctId":"NCT00759148","phase":"PHASE3","title":"Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Bacterial Conjunctivitis","enrollment":1179},{"nctId":"NCT00924729","phase":"PHASE4","title":"Study of Ocular Penetration of Topically Administered Fluoroquinolones","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-09","conditions":"Cataract Extraction","enrollment":50},{"nctId":"NCT00332293","phase":"PHASE3","title":"AL-15469A for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Bacterial Conjunctivitis","enrollment":695},{"nctId":"NCT02865876","phase":"PHASE3","title":"Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis","status":"UNKNOWN","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2015-06","conditions":"Keratitis","enrollment":264},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":"Corneal Ulcers","enrollment":2},{"nctId":"NCT01573910","phase":"PHASE3","title":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-05","conditions":"Bacterial Conjunctivitis","enrollment":985},{"nctId":"NCT00348348","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":1161},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01859702","phase":"PHASE4","title":"Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Cataract","enrollment":36},{"nctId":"NCT00579020","phase":"PHASE2","title":"A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Corneal Infiltrates","enrollment":144},{"nctId":"NCT00312338","phase":"PHASE4","title":"Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-06","conditions":"Bacterial Conjunctivitis","enrollment":137},{"nctId":"NCT00840580","phase":"PHASE4","title":"Effect on Wound Healing of Vigamox Versus Cravit","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-01","conditions":"Cataract Extraction","enrollment":79},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT01455233","phase":"PHASE4","title":"2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery","status":"COMPLETED","sponsor":"Ophthalmology Consultants, Ltd.","startDate":"2010-09","conditions":"Corneal Health, Cataract Surgery","enrollment":60},{"nctId":"NCT00464438","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-06","conditions":"Bacterial Conjunctivitis","enrollment":171},{"nctId":"NCT00732446","phase":"PHASE3","title":"Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-08","conditions":"Blepharitis, Conjunctivitis, Keratitis","enrollment":100},{"nctId":"NCT00870103","phase":"PHASE4","title":"Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Cataract","enrollment":64},{"nctId":"NCT00764582","phase":"PHASE4","title":"Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery","status":"TERMINATED","sponsor":"Santen Inc.","startDate":"2008-09","conditions":"Corneal Transplantation","enrollment":60},{"nctId":"NCT00892918","phase":"NA","title":"Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2009-06","conditions":"Primary Pterygium","enrollment":40},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00630019","phase":"PHASE4","title":"Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-02","conditions":"Cataract","enrollment":96},{"nctId":"NCT00347828","phase":"PHASE4","title":"Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2006-06","conditions":"Eye Infection, Infection","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"recentPublications":[{"date":"2015 May-Jun","pmid":"26065499","title":"Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.","journal":"Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)"},{"date":"2015","pmid":"25999691","title":"Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.","journal":"Clinical ophthalmology (Auckland, N.Z.)"},{"date":"2015 Mar","pmid":"25409447","title":"Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"date":"2014 May","pmid":"24637269","title":"Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.","journal":"Cornea"},{"date":"2014 May","pmid":"24566460","title":"The role of besifloxacin in the treatment of bacterial conjunctivitis.","journal":"The Annals of pharmacotherapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Moxifloxacin ophthalmic solution 0.5%","genericName":"Moxifloxacin ophthalmic solution 0.5%","companyName":"Ophthalmic Consultants of Boston","companyId":"ophthalmic-consultants-of-boston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}